rais pt acceler tripl cf
want top larg cap idea base good upcom
result juli ramp new symdeko cf drug pot updat
phase tripl program includ enrol data/fil timelin
think could ahead consensu low given
tripl pill could start thu consensu need rise
high-qual large-cap idea sinc primari bear case competit
persist last month dissip make ownabl
larg cap growth name generalist especi appetit increas risk-on
biotech environ upcom ep call may
updat phase tripl program think enrol ahead schedul data
file could come earlier guidanc street grow
confid pull away peer ultim creat visibl parabol
earn cycl rais ep estim account
earli tripl pill launch peak earn power could upward
share time chose manag expens lastli behind cf new pipelin
program materi medium- long-term non-opioid pain program
crsp small molecul liver diseas yet none program arein
rais pt key competit glpg
fade could like report phase tripl data earlier-than-
expect month impli potenti nda file earli
approval/launch inde management said initi phase tripl data could
readi earli although believ first set data could readi in-hous
earli fall two tripl fairli ident recent phase ii
data remark pretti similar co may seek review phase data choos
optim regimen
specif tripl began het-min recruit feb
mid-jun respect suggest data aug-dec time-frame note
unclear actual report data timepoint
file sinc two tripl close togeth may wait in-hous phase
dataset pick one file nda disclos street
earli file allow co review data side-by-sid
drug safeti profil choos file fda
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
posit view base belief compani
success develop tripl pill address
cf patient current approv
probabl tripl pill work hetero
patient impli treat pt
long-term
fair probabl remov signific expens
upsid scenario price base appli
multipl ww peak sale
scenario also factor situat
acquir would elimin vrtx expens
assum low discount rate acquir big
similar biotech acquisit last
year atln mdvn other high p/
also consid pipelin valu pain program
downsid scenario price base dcf
base busi includ
think could becom fastest-grow larg cap
biotech due compani tripl pill regimen
cf patient doubl cf franchis revenu
total even higher
importantli think phase tripl data could come
earlier-than-expect allow launch
think key data releas non-cf pipelin could
surpris upsid believ target
potenti ema approv symdeko
potenti addit reimburs orkambi key eu
countri franc region
neg data readout competitor
announc phase data/nda file tripl pill
end year vs guidanc earli
posit phase i/ii data gen
potenti posit data competitor cf space
could better pill
addit reimburs pushback failur expand
commerci opportun eu
potenti safeti toler issu one tripl
page
pleas see import disclosur inform page report
